Sentences with phrase «for docetaxel»

For both populations, though, disease prognosis remains poor: the median progression - free survival for docetaxel - treated patients was 3.4 months, compared with 2.4 months for erlotinib.

The HR for progression for docetaxel vs. erlotinib was 0.70 (P =.019).

The majority of patients included in the study were not eligible for docetaxel because their disease had progressed despite pretreatment with this drug (approximately 57 %).

There were no evaluable data for the docetaxel population.

If prolongation of life was the primary therapeutic objective and the patients were eligible for docetaxel treatment, the G - BA specified docetaxel in combination with prednisone or prednisolone as appropriate comparator therapy (docetaxel population).

The median disease - progression free survival was 3.5 months for those who took nivolumab and 2.8 months for docetaxel.

Not exact matches

Previous results from the trial have already changed clinical practice — data released last year has led to docetaxel chemotherapy now being part of the standard of care for many men with prostate cancer.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

The next generation drug in the taxane family, cabazitaxel, was approved in 2010, but only for patients whose cancer no longer responded to hormone therapy or docetaxel treatment.

Analysis of the tumor genes affected by the two drugs revealed that cabazitaxel had a greater effect on cellular division and regulation of chromatin — a spool for DNA that helps control which genes are in use and when — whereas docetaxel has a greater impact on DNA transcription and repair.

If docetaxel treatment was not an option for the patients or if the primary treatment goal was the relief of symptoms, the so - called «symptom control,» and the prevention of complications, the G - BA specified BSC as appropriate comparator therapy (BSC population).

No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal.

For years, docetaxel has been the only effective chemotherapy for men whose cancer was no longer responding to hormone treatmenFor years, docetaxel has been the only effective chemotherapy for men whose cancer was no longer responding to hormone treatmenfor men whose cancer was no longer responding to hormone treatments.

Results also showed 27.7 percent of patients in the ADT plus docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months compared with 16.8 percent for those taking ADT alone.

Results showed an increased survival of 13.6 months for patients treated with ADT plus docetaxel than with ADT alone.

It included 790 patients (median age of 63 years) who were enrolled and randomized from July 2006 to November 2012 to receive either ADT plus docetaxel every three weeks for six cycles or ADT alone.

The men receiving docetaxel had an average of 32.7 months before the cancer progressed by worsening scan results or symptoms, compared to 19.8 months for hormone therapy alone.

The trial actually enrolled 938 patients with recurrent advanced NSCLC; physicians initially chose pemetrexed or docetaxel for patients, after which patients were randomized to either chemotherapy alone or in addition to a cetuximab regimen.

Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triplenegative breast cancers.

Inclusion Criteria: • The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant and adjuvant therapies will not be considered as a prior line of therapy) for advanced or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy.

The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).

The hazard ratio for progression - free survival was 0.69 in favor of docetaxel (95 % CI, 0.52 — 0.93; P =.014).

Pertuzumab was approved by the FDA in 2012 for first - line treatment of HER2 + metastatic breast cancer in combination with trastuzumab and the chemotherapy docetaxel (Taxotere).

In 2014, researchers at the National Cancer Conference made the following statement: «Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10 - 15 % of patients following docetaxel for EBC [early breast cancer].